Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Analyzed in a New Business Study
Medical institutions and pharmaceutical companies are akin on developing niche products that accelerate schizophrenia therapeutics pertaining to cognitive symptoms. Frontier Pharma, a leading investor in pharmaceutical companies has recently diverted its resources towards innovative drug discovery in schizophrenia. To understand the implications of novel developments in schizophrenia therapeutics for cognitive symptoms, Market Research Hub (MRH) has recently added a new research study titled, 'Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms', to...
View full press release